You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國衞生集團(00673.HK)年度收入約7640萬港元 同比減少29%
格隆匯 06-30 22:04

格隆匯6月30日丨中國衞生集團(00673.HK)公吿,截至2023年3月31日止年度,集團錄得收入約7640萬港元,同比減少29%。集團於年度股東應占虧損約4200萬港元,而上一年度則為虧損淨額約1220萬港元。虧損淨額增加主要由於年內就收購公司一間附屬公司發行代價股份產生或然代價公平值變動虧損約1770萬港元所致。年度每股基本虧損為9.86港仙(2022年:2.96港仙)。

集團透過其位於中國武漢市附屬公司馬格瑞茲(武漢)醫療技術發展有限公司("武漢馬格瑞茲")以及位於中國北京市附屬公司北京佑康健業醫療器械有限公司("北京佑康")運營醫療器械及耗材分銷以及服務業務。

因上半年中國境內新冠疫情蔓延及防控政策收緊,集團的醫療器械及耗材分銷業務受到較大影響,武漢馬格瑞茲的收入大幅下降,發生經營虧損,北京佑康的收入增長出現放緩。

下半年集團已進一步加強現有業務,優化產品組合,發展新客户和新產品,尋求新的業務增長點。特別是北京佑康,已取得多項中標項目,並加強寵物疫苗的市場推廣服務,確保全年業務止跌回穩。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account